Short Interest in Genprex, Inc. (NASDAQ:GNPX) Declines By 5.9%

Genprex, Inc. (NASDAQ:GNPX) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 342,100 shares, a drop of 5.9% from the October 31st total of 363,400 shares. Based on an average trading volume of 9,330,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 4.3% of the shares of the stock are short sold.

Hedge Funds Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC grew its holdings in Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 218,000 shares of the company’s stock after purchasing an additional 120,132 shares during the period. Armistice Capital LLC owned about 10.39% of Genprex worth $411,000 as of its most recent SEC filing. 14.05% of the stock is owned by institutional investors.

Genprex Price Performance

GNPX stock traded up $0.01 during mid-day trading on Tuesday, reaching $1.10. 1,795,534 shares of the stock traded hands, compared to its average volume of 1,901,165. Genprex has a 52-week low of $0.28 and a 52-week high of $14.40. The stock’s fifty day moving average is $1.19 and its 200-day moving average is $1.44.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.